SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, today announced it has launched three new seroconversion panels that provide difficult-to-find patient samples for Hepatitis B and HIV. The company’s newest offerings expand its robust line of seroconversion panels focusing on infectious disease.

“SeraCare recognizes the challenges our customers face in testing their assays rigorously while meeting complex and evolving regulatory requirements,” said John Wyatt, Director, Research Business Unit at SeraCare. “To provide our customers with the most innovative solutions, SeraCare continually enhances our infectious disease panels to deliver the unique patient samples they need to thoroughly challenge their assays.” The company’s unrivaled global sourcing network places it in a unique position to find and source these distinct patient samples.

SeraCare’s three new seroconversion panels have been tested on today’s market-leading assays. Each panel represents a single donor and demonstrates how that donor’s blood converts in the presence of the disease during the sample collection period, presenting a unique challenge to the assay. Each product’s data sheet provides a graphical depiction of the donor’s seroconversion, along with comparative data that enables customers to review their test results against the results of other industry assays.

HBV Seroconversion Panel (PHM938) comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA positive from the first bleed.

HBV Seroconversion Panel (PHM939) provides five undiluted plasma samples from a single donor drawn over a 21-day period and is also HBV DNA positive from the first bleed. These panels allow for challenging members for HBsAg assays and HBeAg assays, delivering results for both rapid and qualitative HBsAg methods.

HIV-1 Seroconversion Panel (PRB978) provides seven undiluted plasma samples from a single donor and is designed to challenge HIV RNA positive members on traditional antibody methods.

Designed to help maintain high standards for assay development, regulatory compliance and method development, SeraCare’s extensive line of seroconversion panels includes a variety of options for HIV, Hepatitis A, Hepatitis B, Hepatitis C and West Nile Virus. These panels help diagnostics manufacturers and clinical labs evaluate, monitor and troubleshoot assay performance. The panels are derived from undiluted samples from single donors after their exposure to an infectious disease and subsequent immune response.

SeraCare’s new HBV and HIV seroconversion panels are available immediately worldwide.

For more information, contact SeraCare Customer Service at 1-800-676-1881 or visit www.seracare.com.

About SeraCare Life Sciences, Inc.

SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN^® quality controls, research panels, SeraCon^® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics.

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare.

For additional information about Linden, please refer to the firm's website at www.lindenllc.com.